Welcome to our dedicated page for Penumbra SEC filings (Ticker: PEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Penumbra, Inc. filings document the regulatory record for a NYSE-listed medical-device company focused on thrombectomy technologies for stroke, pulmonary embolism, venous thromboembolism, and acute limb ischemia. Form 8-K reports cover operating results, material-event disclosures, material agreements, capital-structure matters, and clinical or regulatory updates involving its thrombectomy portfolio.
Proxy materials describe shareholder voting matters, governance practices, compensation arrangements, and capital-structure proposals. The filing record also includes disclosures on risk factors, financial condition, executive appointments and compensatory arrangements, and the company's common stock registered under the symbol PEN on the New York Stock Exchange.
Penumbra (PEN) – CEO Adam Elsesser Form 4 filing (23 Jul 2025):
The CEO exercised 27,976 stock options at a $30 strike that were set to expire on 16 Sep 2025, immediately selling 16,150 shares under a pre-arranged Rule 10b5-1 plan at weighted-average prices of $232-$234. After the transactions, his direct ownership increased to 146,258 common shares, while he still holds 577,582 shares through the Siegel/Elsesser Revocable Trust and 83,932 fully vested options.
Proceeds from the sale likely funded the exercise price and tax obligations. The filing does not signal operational changes and leaves the CEO with a substantial equity position, but the market may view the discretionary share sales as a mildly negative sentiment indicator.
Penumbra, Inc. (PEN) – Form 4 insider transaction filed 07/11/2025
Chief Executive Officer and President Adam Elsesser reported an option exercise (Code M) and subsequent open-market sales executed under a pre-arranged Rule 10b5-1 trading plan on 07/09/2025:
- Exercised: 27,976 common shares at an exercise price of $30.00.
- Sold: 15,985 common shares across eight trades at weighted-average prices ranging from $241.09 to $248.79.
After these transactions, Elsesser’s holdings are:
- Direct ownership: 134,432 common shares.
- Indirect ownership: 577,582 common shares held by the Siegel/Elsesser Revocable Trust.
- Derivative holdings: 111,908 vested stock options remaining.
The filing indicates that sales were made primarily to cover the exercise price and associated tax withholdings related to the expiring options. No other corporate events or financial results are disclosed in this filing.
Penumbra, Inc. (PEN) – Form 4 insider transaction
Executive Vice President, General Counsel & Secretary Johanna Roberts reported the exercise of employee stock options on 25 June 2025 (transaction code M). She converted 1,943 stock-option units with an exercise price of $22.04 into an equal number of common shares. All options were already fully vested and would have expired on 11 Aug 2025.
Following the exercise, Roberts’ direct beneficial ownership increased to 66,657 PEN shares. No derivative securities remain outstanding from this grant, and the filing discloses no concurrent sale of the acquired shares.
The transaction was filed individually by the reporting person on 27 June 2025.
Penumbra (NYSE:PEN) filed a Form 4 detailing insider transactions by CEO Adam Elsesser.
- Options exercised: 27,976 shares at $30
- Shares sold: 15,890 at an average ≈$253; gross proceeds ≈$4.0 million
- Ownership after trade: 122,441 direct shares and 577,582 indirect shares via trust (≈700k total)
- Sale magnitude: ~2.3% of post-transaction holdings but above the $1 million materiality threshold
Sales were executed under a pre-arranged Rule 10b5-1 plan tied to option expiration on 09/16/2025, suggesting liquidity and tax-coverage motives rather than discretionary selling.
Form 144 Notice of Proposed Sale filed by Adam Elsesser of Penumbra indicates planned sale of 15,890 shares of common stock with an aggregate market value of $4,026,584.79. The sale is scheduled for June 25, 2025, through Morgan Stanley Smith Barney LLC on the NYSE.
The shares were acquired through a stock option exercise on June 25, 2025, with cash payment. The filing reveals significant recent selling activity by Elsesser over the past 3 months:
- June 11, 2025: 15,910 shares for $4.04M
- May 28, 2025: 16,300 shares for $4.37M
- May 14, 2025: 16,600 shares for $4.95M
- May 7, 2025: 16,650 shares for $4.82M
- April 16, 2025: 16,560 shares for $4.54M
- April 2, 2025: 16,565 shares for $4.51M
Total shares outstanding: 38,725,940. The seller affirms no knowledge of undisclosed material adverse information regarding Penumbra's operations.